Pediatrix Medical Group, Inc. $MD Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lessened its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 77.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,716 shares of the company’s stock after selling 504,961 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.17% of Pediatrix Medical Group worth $2,407,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. American Century Companies Inc. increased its stake in Pediatrix Medical Group by 38.9% in the 3rd quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after buying an additional 751,109 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Pediatrix Medical Group by 20.5% in the third quarter. JPMorgan Chase & Co. now owns 827,075 shares of the company’s stock valued at $13,854,000 after acquiring an additional 140,577 shares in the last quarter. Dana Investment Advisors Inc. boosted its holdings in shares of Pediatrix Medical Group by 5.6% in the third quarter. Dana Investment Advisors Inc. now owns 801,462 shares of the company’s stock valued at $13,424,000 after acquiring an additional 42,162 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Pediatrix Medical Group by 175.4% during the second quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock worth $10,683,000 after acquiring an additional 474,186 shares during the period. Finally, Qube Research & Technologies Ltd raised its holdings in Pediatrix Medical Group by 2.0% during the second quarter. Qube Research & Technologies Ltd now owns 735,526 shares of the company’s stock worth $10,555,000 after purchasing an additional 14,596 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on MD shares. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Truist Financial dropped their price objective on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, February 19th. Zacks Research cut Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. Finally, UBS Group decreased their target price on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and an average price target of $19.80.

Insider Buying and Selling

In related news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. This represents a 7.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.90% of the company’s stock.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $19.29 on Friday. The stock has a fifty day moving average price of $21.16 and a 200 day moving average price of $19.88. The stock has a market cap of $1.60 billion, a PE ratio of 9.94 and a beta of 0.79. Pediatrix Medical Group, Inc. has a 1 year low of $11.84 and a 1 year high of $24.99. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.03). Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The firm had revenue of $493.77 million during the quarter, compared to analyst estimates of $486.23 million. During the same period last year, the company posted $0.51 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.